Equity Profile

HALO

Halozyme Therapeutics, Inc.

Health CareBiotechnology$9.0B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Halozyme is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market demand and overall business health, especially in the competitive biotech landscape.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. Operating in the health care sector, Halozyme is known for its proprietary drug delivery technology, which enhances the effectiveness of existing therapies and potentially improves patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In the last quarter, Halozyme reported an EPS of $1.60, exceeding estimates by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally optimistic about Halozyme's upcoming earnings, given its strong historical performance in beating EPS estimates.

Bull Case

If Halozyme continues its trend of beating EPS estimates, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given Halozyme's strong track record of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What insights can management provide regarding revenue growth and future guidance?

Management's commentary on revenue trends will be crucial for understanding the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Halozyme's ability to leverage its proprietary technology for revenue growth, especially in light of recent positive trends in the biotech sector.

Supporting Evidence

Halozyme has consistently beaten EPS estimates, indicating strong operational efficiency.

The options market is pricing a significant move, suggesting that traders expect more volatility than the Street is prepared for.

Key Risk

If the EPS comes in above $1.70, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Halozyme's ability to maintain its growth trajectory against potential headwinds in the biotech sector.

Bull Confirmed If

An EPS of $1.70 or higher would confirm the bullish outlook, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.40 would signal potential issues in profitability and could lead to a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests the stock could rise by around 0.49% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience minimal movement.

Miss

A miss on EPS could lead to a decline of about 1.31%, reflecting disappointment in the market.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could drive revenue growth.
2Management's outlook on the competitive landscape in the biotech sector.
3Details on any new product launches or pipeline developments.
4Insights into cost management strategies and their impact on profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Halozyme is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market demand and overall business health, especially in the competitive biotech landscape.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In the last quarter, Halozyme reported an EPS of $1.60, exceeding estimates by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally optimistic about Halozyme's upcoming earnings, given its strong historical performance in beating EPS estimates.

Bull Case

If Halozyme continues its trend of beating EPS estimates, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given Halozyme's strong track record of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What insights can management provide regarding revenue growth and future guidance?

Management's commentary on revenue trends will be crucial for understanding the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Halozyme's ability to leverage its proprietary technology for revenue growth, especially in light of recent positive trends in the biotech sector.

Supporting Evidence

Halozyme has consistently beaten EPS estimates, indicating strong operational efficiency.

The options market is pricing a significant move, suggesting that traders expect more volatility than the Street is prepared for.

Key Risk

If the EPS comes in above $1.70, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Halozyme's ability to maintain its growth trajectory against potential headwinds in the biotech sector.

Bull Confirmed If

An EPS of $1.70 or higher would confirm the bullish outlook, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.40 would signal potential issues in profitability and could lead to a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests the stock could rise by around 0.49% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience minimal movement.

Miss

A miss on EPS could lead to a decline of about 1.31%, reflecting disappointment in the market.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could drive revenue growth.
2Management's outlook on the competitive landscape in the biotech sector.
3Details on any new product launches or pipeline developments.
4Insights into cost management strategies and their impact on profitability.